The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).

Main inclusion criteria:

• Patients with severe, chronic pain

Main exclusion criteria:

• Hypersensitivity of fentanyl
• Co-administration of monoaminooxidase-inhibitors
• Pregnancy
• Respiratory depression
• Chronic obstructive pulmonary disease (COPD)
• Drug abuse
• Impairment of CNS functions
• Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)

Outpatients